Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1996 11
1997 11
1998 14
1999 11
2000 5
2001 1
2008 2
2009 2
2011 1
2012 1
2014 1
2017 1
2018 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Results by year

Filters applied: . Clear all
Page 1
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Salloway S, et al. N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839. N Engl J Med. 2014. PMID: 24450891 Free PMC article. Clinical Trial.
The "co-pilot" driver syndrome.
Shua-Haim JR, Gross JS. Shua-Haim JR, et al. J Am Geriatr Soc. 1996 Jul;44(7):815-7. doi: 10.1111/j.1532-5415.1996.tb03739.x. J Am Geriatr Soc. 1996. PMID: 8675930 No abstract available.
Depression among Alzheimer's caregivers: identifying risk factors.
Shua-Haim JR, Haim T, Shi Y, Kuo YH, Smith JM. Shua-Haim JR, et al. Am J Alzheimers Dis Other Demen. 2001 Nov-Dec;16(6):353-9. doi: 10.1177/153331750101600611. Am J Alzheimers Dis Other Demen. 2001. PMID: 11765860 Free PMC article.
Efficacy and Safety of Plasma Exchange with 5% Albumin to Modify Cerebrospinal Fluid and Plasma Amyloid-β Concentrations and Cognition Outcomes in Alzheimer's Disease Patients: A Multicenter, Randomized, Controlled Clinical Trial.
Boada M, Anaya F, Ortiz P, Olazarán J, Shua-Haim JR, Obisesan TO, Hernández I, Muñoz J, Buendia M, Alegret M, Lafuente A, Tárraga L, Núñez L, Torres M, Grifols JR, Ferrer I, Lopez OL, Páez A. Boada M, et al. Among authors: shua haim jr. J Alzheimers Dis. 2017;56(1):129-143. doi: 10.3233/JAD-160565. J Alzheimers Dis. 2017. PMID: 27911295 Free PMC article. Clinical Trial.
62 results